| 摘要 |
The present invention relates to a pharmaceutical composition for inhibiting metastasis of solid cancer and/or increasing sensitivity to radiation and anticancer drugs, containing oxytocin as an active ingredient and also as an agent for enhancing expression of early growth response 1 (EGR1). According to the present invention, the composition can be used as a composite treatment agent along with existing anticancer drugs by effectively inhibiting cancer metastasis. In addition, the composition can also be used in complex therapies in conjunction with radiotherapy by injecting the composition prior to radiotherapy. |
